MentionFox
Home › IPO pipeline › Iambic Therapeutics, Inc.
IPO filings · Form S-1, F-1, 424B4, RW

Iambic Therapeutics, Inc. IPO

Iambic Therapeutics, Inc.'s initial public offering: every registration filing, amendment, final prospectus and withdrawal, with the facts quoted from the filings and each one linked.

StatusFiled
TickerIAM
ExchangeNasdaq Global Select Market
First filed2026-09-21
Filings1

Iambic Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2026-09-21. As of its latest filing, on 2026-09-21, it has not priced the offering or withdrawn it. Each fact below is quoted from the filing named with it.

What the filings say

Listing

We have applied to list our common stock on The Nasdaq Global Select Market under the symbol “IAM” and this offering is contingent upon obtaining approval of such listing.From the S-1 filed 2026-09-21

Use of proceeds

We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to advance the clinical development of IAM1363; to advance the clinical development of IAM217 through ; to advance the clinical development of IAM-C1 through ; and the remainder, if any, for working capital and other general corporate purposes.From the S-1 filed 2026-09-21

Net loss or income

Our net losses were $77.3 million and $47.9 million for the years ended December 31, 2025 and 2024, respectively, and $50.1 million for the six month period ended June 30, 2026.From the S-1 filed 2026-09-21

Timeline

FiledWhat it isFiling
2026-09-21Registration statement filedS-1

Tools for this story

Each opens in a new tab, filled in for Iambic Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.

Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.

Cite this page

Permanent URL: https://mentionfox.com/ipo/iambic-therapeutics
Last updated 2026-09-27
Primary record: SEC filing
Iambic Therapeutics, Inc. IPO (IAM, Nasdaq Global Select Market): registration filed. MentionFox, 2026-09-27. https://mentionfox.com/ipo/iambic-therapeutics